Ocular Therapeutix Statistics
Total Valuation
OCUL has a market cap or net worth of $690.37 million. The enterprise value is $576.19 million.
| Market Cap | 690.37M |
| Enterprise Value | 576.19M |
Important Dates
The next estimated earnings date is Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OCUL has 148.63 million shares outstanding. The number of shares has increased by 3.57% in one year.
| Shares Outstanding | 148.63M |
| Shares Change (YoY) | +3.57% |
| Shares Change (QoQ) | +6.00% |
| Owned by Insiders (%) | 3.68% |
| Owned by Institutions (%) | 50.07% |
| Float | 128.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.81 |
| Forward PS | 10.14 |
| PB Ratio | 7.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.66, with a Debt / Equity ratio of 0.92.
| Current Ratio | 6.66 |
| Quick Ratio | 6.41 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.12 |
Financial Efficiency
Return on equity (ROE) is -288.90% and return on invested capital (ROIC) is -47.20%.
| Return on Equity (ROE) | -288.90% |
| Return on Assets (ROA) | -48.50% |
| Return on Capital (ROIC) | -47.20% |
| Revenue Per Employee | $218,888 |
| Profits Per Employee | -$302,382 |
| Employee Count | 267 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 2.47 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.08% in the last 52 weeks. The beta is 1.32, so OCUL's price volatility has been higher than the market average.
| Beta (1Y) | 1.32 |
| 52-Week Price Change | -25.08% |
| 50-Day Moving Average | 8.59 |
| 200-Day Moving Average | 4.92 |
| Relative Strength Index (RSI) | 16.84 |
| Average Volume (30 Days) | 2,353,762 |
Short Selling Information
The latest short interest is 11.81 million, so 7.94% of the outstanding shares have been sold short.
| Short Interest | 11.81M |
| Short Previous Month | 9.16M |
| Short % of Shares Out | 7.94% |
| Short % of Float | 9.19% |
| Short Ratio (days to cover) | 4.84 |
Income Statement
In the last 12 months, OCUL had revenue of $58.44 million and -$80.74 million in losses. Loss per share was -$1.02.
| Revenue | 58.44M |
| Gross Profit | 53.16M |
| Operating Income | -82.38M |
| Pretax Income | -80.74M |
| Net Income | -80.74M |
| EBITDA | -66.42M |
| EBIT | -69.40M |
| Loss Per Share | -$1.02 |
Balance Sheet
The company has $197.57 million in cash and $83.39 million in debt, giving a net cash position of $114.18 million or $0.77 per share.
| Cash & Cash Equivalents | 197.57M |
| Total Debt | 83.39M |
| Net Cash | 114.18M |
| Net Cash Per Share | $0.77 |
| Equity / Book Value | 91.13M |
| Book Value Per Share | 0.61 |
| Working Capital | 197.34M |
Cash Flow
In the last 12 months, operating cash flow was -$70.23 million and capital expenditures -$6.09 million, giving a free cash flow of -$76.32 million.
| Operating Cash Flow | -70.23M |
| Capital Expenditures | -6.09M |
| Free Cash Flow | -76.32M |
| FCF Per Share | -$0.96 |
Margins
Gross margin is 90.96%, with operating and profit margins of -140.96% and -138.14%.
| Gross Margin | 90.96% |
| Operating Margin | -140.96% |
| Pretax Margin | -138.14% |
| Profit Margin | -138.14% |
| EBITDA Margin | -113.64% |
| EBIT Margin | -118.74% |
| FCF Margin | -130.59% |
Dividends & Yields
OCUL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.57% |
| Shareholder Yield | -3.57% |
| Earnings Yield | -11.69% |
| FCF Yield | -11.06% |
Analyst Forecast
The average price target for OCUL is $16.50, which is 255.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.50 |
| Price Target Difference | 255.22% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 46.81% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OCUL has an Altman Z-Score of -1.04 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.04 |
| Piotroski F-Score | 3 |